Abstract: In Western developed countries, precision nuclear medicine diagnosis and treatment for neuroendocrine neoplasms (NENs) have been widely adopted in clinical practice. Over the past two decades, China has made significant progress in both research and clinical application of nuclear medicine-based NENs management. With internationally approved diagnostic and therapeutic agents soon entering the Chinese market and the ongoing clinical trials of domestically developed innovative drugs, there is an urgent need to establish standardized diagnostic and treatment guideline. To address this, the Chinese Society of Nuclear Medicine and the Chinese Neuroendocrine Tumor Society have collaborated to develop the Clinical Guideline for Precision Nuclear Medicine Diagnosis and Treatment of Neuroendocrine Neoplasms (2025 Edition). The guideline integrates the latest research advances and international recommendations with China's clinical practice, aiming to standardize and optimize NENs management through nuclear medicine in China.